Used in the treatment of melanoma and other cancers with BRAF V600 mutations, dabrafenib works by inhibiting the overactive BRAF protein that drives uncontrolled cell growth. It is particularly effective in patients with unresectable or metastatic melanoma and is also used in combination with trametinib, a MEK inhibitor, to improve response rates and delay resistance. The drug has shown benefit in treating non-small cell lung cancer and anaplastic thyroid cancer with the same genetic mutation. Dabrafenib helps shrink tumors and prolong progression-free survival, making it a key component of targeted cancer therapy for BRAF-positive cancers.